Q3 net sales from continuing operations1were in line with prior year (cc2, +1% USD):
Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1 012 million (+7% cc), Kisqali USD 183 million (+50% cc) and Promacta/Revolade USD 442 million (+16% cc)
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00English RSS Feedhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngEnglish RSS Feed2020-10-27 07:00:002020-10-27 07:00:00Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.
Q3 net sales from continuing operations1were in line with prior year (cc2, +1% USD):
Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1 012 million (+7% cc), Kisqali USD 183 million (+50% cc) and Promacta/Revolade USD 442 million (+16% cc)
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00https://www.sandoz.com/rss/feeds/news/media-releases.xmlhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pnghttps://www.sandoz.com/rss/feeds/news/media-releases.xml2020-10-27 02:00:002020-10-27 02:00:00Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.
